2 Pages
English

Absence of Alternative Therapies for Psoriatic Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan

Gain access to the library to view online
Learn more

Description

Absence of Alternative Therapies for Psoriatic Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan PR Newswire MOUNTAIN VIEW, California, Oct. 25, 2012 - Pharmaceutical companies need to introduce safe and effective therapies for patients that do not respond to TNF inhibitors MOUNTAIN VIEW, California, Oct. 25, 2012 /PRNewswire/ -- Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of care. This represents a significant unmet need for alternative therapies for TNF inhibitor refractory patients. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com) United States Market for Psoriatic Arthritis Pharmacotherapy research finds that psoriatic arthritis pharmacotherapeutics prescribed as add-on therapies to standard background therapy earned revenues of approximately $751.5 million in 2011. Frost & Sullivan estimates this to reach $1.3 billion in 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. TNF inhibitors, a well-established drug class, have laid the groundwork for the next-generation of effective disease modifying antirheumatic drugs and biologics with improved safety and efficacy profiles.

Subjects

Informations

Published by
Reads 15
Language English
Absence of Alternative Therapies for Psoriatic Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan
PR Newswire MOUNTAIN VIEW, California, Oct. 25, 2012
- Pharmaceutical companies need to introduce safe and effective therapies for patients that do not respond to TNF inhibitors
MOUNTAIN VIEW, California,Oct. 25, 2012/PRNewswire/ -- Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of care. This represents a significant unm et need for alternative therapies for TNF inhibitor refractory patients.
New analysis from Frost & Sullivan's (http://www.healthcare.frost.com)United States Market for Psoriatic Arthritis Pharmacotherapyresearch finds that psoriatic arthritis pharmacotherapeutics prescribed as add-on therapies to standard background therapy earned revenues of approximately$751.5 millionin 2011. Frost & Sullivan estimates this to reach$1.3 billionin 2017.
If you are interested in more information on this research, please send an email toBritni Myers, Corporate Communications, atbritni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
TNF inhibitors, a well-established drug class, have laid the groundwork for the next-generation of effective disease modifying antirheumatic drugs and biologics with im proved safety and efficacy profiles. The development of novel therapies for this complex disease, however, is hindered by several factors, such as an incompletely understood pathogenesis and a perception that PsA is a milder disease than rheumatoid arthritis. In addition, dermatologists may be less inclined than rheumatologists to prescribe biologics, hindering acceptance of these valuable treatments within the physician community. Consequently, TNF inhibitors are likely to continue as the first line of treatment for PsA, initially limiting the uptake of new agents to second line use.
"While some TNF inhibitors that are effective in rheumatoid arthritis are also effective in PsA, patients with moderate to severe forms of the disease may not alw ays respond to them," saidFrost & Sullivan Senior Industry Analyst Debbie Toscano. "This creates a strong need for alternative therapies."
To improve their therapies' commercial acceptance, pharmaceutical companies need to raise the level of disease awareness and alter the perception of the potential severity of PsA. In addition, robust data supporting the clinical benefits of new agents in comparison with TNF inhibitors can help to overcome the entrenchment of this class and win over payers, prescribers and patients.
"With the impending launch of three new therapies for the treatment of PsA in 2014, the awareness of PsA is expected to increase substantially," noted Toscano. "This will renew interest in PsA, as patients and physicians will finally be presented with alternative treatments."
United States Market for Psoriatic Arthritis Pharmacotherapyis part of theLife SciencesGrowth Partnership Services program, which also includes research in the following markets: United States Market for Rheumatoid Arthritis Pharmacotherapy, United States Rheumatic Diseases Therapeutics Market, United States Market for Ankylosing Spondylitis Pharmacotherapy, and U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, w orks in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Propositionprovides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation. The Partnership Infrastructureis entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of m ore than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry